Paradigm Capital Management Inc. NY Reduces Position in PerkinElmer, Inc. (PKI)
Paradigm Capital Management Inc. NY decreased its holdings in PerkinElmer, Inc. (NYSE:PKI) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 80,200 shares of the medical research company’s stock after selling 2,100 shares during the quarter. Paradigm Capital Management Inc. NY’s holdings in PerkinElmer were worth $5,865,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. King Luther Capital Management Corp boosted its holdings in shares of PerkinElmer by 1.3% in the third quarter. King Luther Capital Management Corp now owns 2,562,833 shares of the medical research company’s stock worth $176,759,000 after buying an additional 32,248 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of PerkinElmer by 9.9% in the third quarter. Ameriprise Financial Inc. now owns 955,790 shares of the medical research company’s stock worth $65,923,000 after buying an additional 86,395 shares during the last quarter. Schroder Investment Management Group boosted its holdings in shares of PerkinElmer by 10.1% in the third quarter. Schroder Investment Management Group now owns 903,667 shares of the medical research company’s stock worth $61,757,000 after buying an additional 82,769 shares during the last quarter. American Century Companies Inc. purchased a new position in shares of PerkinElmer in the fourth quarter worth approximately $61,260,000. Finally, Impax Asset Management LTD boosted its holdings in shares of PerkinElmer by 7.3% in the third quarter. Impax Asset Management LTD now owns 718,437 shares of the medical research company’s stock worth $49,551,000 after buying an additional 48,647 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.
A number of equities analysts recently issued reports on the stock. Robert W. Baird reissued a “buy” rating and issued a $72.00 price objective on shares of PerkinElmer in a report on Friday, October 20th. Bank of America raised shares of PerkinElmer from an “underperform” rating to a “neutral” rating and set a $78.00 price objective on the stock in a report on Tuesday, December 19th. Barclays raised their price objective on shares of PerkinElmer from $69.00 to $73.00 and gave the stock an “underweight” rating in a report on Friday, January 26th. ValuEngine downgraded shares of PerkinElmer from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Finally, Jefferies Group reissued a “hold” rating and issued a $70.00 price objective on shares of PerkinElmer in a report on Friday, October 20th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $76.85.
PerkinElmer (NYSE:PKI) last issued its quarterly earnings results on Thursday, January 25th. The medical research company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.03. PerkinElmer had a net margin of 12.97% and a return on equity of 13.30%. The business had revenue of $641.63 million for the quarter, compared to the consensus estimate of $619.14 million. During the same quarter in the previous year, the firm earned $0.83 earnings per share. The company’s revenue for the quarter was up 13.2% on a year-over-year basis. equities research analysts forecast that PerkinElmer, Inc. will post 3.52 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, May 10th. Shareholders of record on Friday, April 13th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.38%. The ex-dividend date of this dividend is Thursday, April 12th. PerkinElmer’s dividend payout ratio is currently 10.61%.
In other PerkinElmer news, Director Alexis P. Michas sold 5,000 shares of PerkinElmer stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $73.18, for a total transaction of $365,900.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Peter Barrett sold 7,071 shares of PerkinElmer stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $71.07, for a total transaction of $502,535.97. Following the transaction, the director now directly owns 26,271 shares in the company, valued at approximately $1,867,079.97. The disclosure for this sale can be found here. Insiders have sold 66,883 shares of company stock worth $4,766,399 in the last ninety days. Insiders own 2.20% of the company’s stock.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.